Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/10/23 16:24:54」(JST)

wiki en

Rasburicase (brand names: Elitek in the US, and Fasturtec in Europe ) is a recombinant version of urate oxidase, an enzyme which occurs in many mammals, but not in humans.

Uses

Rasburicase is approved for use by the U.S. Food and Drug Administration (and European counterparts) for the prevention and treatment of tumor lysis syndrome (TLS)^[1] in patients receiving chemotherapy for hematologic cancers such as leukemias and lymphomas. It is also being investigated for treating severe hyperuricemia from other sources (e.g., gout^[2] and other rheumatologic conditions).

It catalyses the conversion of uric acid to allantoin. Allantoin is an inactive metabolite of purine metabolism, and is five to ten times more soluble than uric acid, so renal excretion is more effective. Rasburicase is unique as a treatment and prevention for renal failure associated with TLS in that it catalyses the metabolism of existing uric acid. Other options prevent uric acid formation.

Rasburicase reduces the risk of renal failure and the need for transfusion. Transfusion has been reported as required in 17 to 25% of TLS cases treated with allopurinol, and 1.4% of cases treated with rasburicase.^{[citation needed]}

However, rasburicase is much more expensive than conventional therapy.^[3]

Side effects

Side effects of rasburicase administration can include anaphylaxis (incidence unknown) and methemoglobinemia.

References

^ Ho VQ, Wetzstein GA, Patterson SG, Bradbury R (April 2006). "Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome". Supportive cancer therapy 3 (3): 178–82. doi:10.3816/SCT.2006.n.016. PMID 18632493. http://cigjournals.metapress.com/openurl.asp?genre=article&id=doi:10.3816/SCT.2006.n.016.
^ Cammalleri L, Malaguarnera M (2007). "Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout". International journal of medical sciences 4 (2): 83–93. PMC 1838823. PMID 17396159. http://www.medsci.org/v04p0083.htm.
^ Reinders MK, van Roon EN, Brouwers JR, Jansen TL (March 2005). "A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?". Annals of the rheumatic diseases 64 (3): 516; author reply 516. doi:10.1136/ard.2003.017087corr1. PMC 1755382. PMID 15708917. http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=15708917.

External links

Elitek (Rasburicase) - Official web site of manufacturer.
Elitek (Rasburicase) Prescribing Information - Official Prescribing Information of manufacturer.
[1] - Elitek (Rasburicase)

This enzyme-related article is a stub. You can help Wikipedia by expanding it.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 腫瘍崩壊症候群：予防および治療 tumor lysis syndrome prevention and treatment
2. 再発性の痛風の予防：薬理学的尿酸低下療法および痛風結節の治療 prevention of recurrent gout pharmacologic urate lowering therapy and treatment of tophi
3. 腫瘍崩壊症候群：定義、発病メカニズム、臨床症状、原因および危険因子 tumor lysis syndrome definition pathogenesis clinical manifestations etiology and risk factors
4. 尿酸による腎疾患 uric acid renal diseases
5. グルコース-6-リン酸脱水素酵素欠損症の診断とマネージメント diagnosis and management of glucose 6 phosphate dehydrogenase deficiency

English Journal

[Analysis of the 2015 British guidelines on the prevention and management of tumor lysis syndrome].

Dupré A1, Mousseaux C1, Bouguerba A1, Ayed S1, Barchazs J1, Boukari M1, Goldgran-Toledano D1, Bornstain C1, Vincent F2; pour le Groupe de recherche en réanimation respiratoire en Onco-Hématologie (GrrrOH).
La Revue de medecine interne.Rev Med Interne.2016 Sep 19. pii: S0248-8663(16)30535-5. doi: 10.1016/j.revmed.2016.08.021. [Epub ahead of print]
Whether it appears spontaneously or is induced by therapy, the tumor lysis syndrome is responsible for a massive release of ions and puric bases degradation of products in the circulation exceeding the renal excretion capacity. Some, such as uric acid, xanthine, and calcium phosphate, can precipitat
PMID 27659746

Rasburicase for Tumor Lysis Syndrome.

Vishwanathan S1, Arumugarajah A, Ortega LM, Bousamra A.
American journal of therapeutics.Am J Ther.2016 Aug 18. [Epub ahead of print]
PMID 27563802

Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT).

Christensen HD1, Sheta HM2, Morillon MB1, Hansen IM1.
The American journal of case reports.Am J Case Rep.2016 Jul 15;17:494-8.
BACKGROUND Gout is characterized by deposition of uric acid crystals (monosodium urate) in tissues and fluids. This can cause acute inflammatory arthritis. The 2015 ACR/EULAR criteria for the diagnosis of gout include dual energy computed tomography (DECT)-demonstrated monosodium urate crystals as a
PMID 27418121

Japanese Journal

症例化学療法後に腫瘍崩壊症候群を発症しラスブリカーゼ投与により改善した肺大細胞神経内分泌癌の1例

鈴木洋平,佐藤匡,髙木陽 [他]
日本呼吸器学会誌 = Annals of the Japanese Respiratory Society 2(6), 746-750, 2013-11-10
NAID 40019892530

ガイドライン(標準治療) 腫瘍崩壊症候群 (第75回日本血液学会学術集会教育講演特集号) -- (その他)

石澤賢一
臨床血液 54(10), 2006-2013, 2013-10
NAID 40019806295

腫瘍崩壊症候群 (特集オンコロジーエマージェンシーと支持療法の進歩)

渡部真人,山田耕三
呼吸器内科 23(3), 244-250, 2013-03
NAID 40019674033

「ラスブリカーゼ」

Rasburicase
Systematic (IUPAC) name
	Aspergillus urate oxidase
Clinical data
AHFS/Drugs.com	monograph
Pregnancy cat.	?
Legal status	RX/POM
Routes	Intravenous
Pharmacokinetic data
Bioavailability	N/A
Half-life	18 hrs
Identifiers
CAS number	134774-45-1
ATC code	V03AF07
DrugBank	DB00049
UNII	08GY9K1EUO
ChEMBL	CHEMBL1201594
Chemical data
Formula	C1521H2381N417O461S7
Mol. mass	34109.5
(what is this?) (verify);

　　[★]

英: rasburicase
化: ラスリテック
関: 酵素製剤

[pmid18632493-0] Ho VQ, Wetzstein GA, Patterson SG, Bradbury R (April 2006). "Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome". Supportive cancer therapy 3 (3): 178–82. doi:10.3816/SCT.2006.n.016. PMID 18632493. http://cigjournals.metapress.com/openurl.asp?genre=article&id=doi:10.3816/SCT.2006.n.016.

[pmid17396159-1] Cammalleri L, Malaguarnera M (2007). "Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout". International journal of medical sciences 4 (2): 83–93. PMC 1838823. PMID 17396159. http://www.medsci.org/v04p0083.htm.

[pmid15708917-2] Reinders MK, van Roon EN, Brouwers JR, Jansen TL (March 2005). "A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?". Annals of the rheumatic diseases 64 (3): 516; author reply 516. doi:10.1136/ard.2003.017087corr1. PMC 1755382. PMID 15708917. http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=15708917.

匿名

検索

案内

案内

rasburicase